| DIRECT COMPETITOR COMPARISON | |
| VIVO | ABT | BDX | Pvt1 | Industry | | Market Cap: | 840.41M | 83.65B | 17.89B | N/A | 62.33M | | Employees: | N/A | 69,000 | 29,000 | N/A | 56 | | Qtrly Rev Growth (yoy): | 16.40% | 3.50% | 3.40% | N/A | 18.90% | | Revenue (ttm): | 148.27M | 29.92B | 7.16B | N/A | 12.73M | | Gross Margin (ttm): | 62.58% | 58.31% | 52.55% | N/A | 50.63% | | EBITDA (ttm): | 53.27M | 8.64B | 2.12B | N/A | -1.76M | | Oper Margins (ttm): | 32.90% | 22.32% | 23.05% | N/A | -19.80% | | Net Income (ttm): | 32.76M | 5.60B | 1.21B | N/A | N/A | | EPS (ttm): | 0.797 | 3.691 | 4.990 | N/A | N/A | | P/E (ttm): | 26.02 | 14.65 | 14.97 | N/A | 23.64 | | PEG (5 yr expected): | 1.36 | 1.27 | 1.3 | N/A | 1.36 | | P/S (ttm): | 5.73 | 2.81 | 2.52 | N/A | 3.09 |
|
| BIOTECHNOLOGY COMPANIES RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Amgen Inc. | AMGN | 56.50 | -1.02% | 57.19B | 12.32 | | Genentech, Inc. | Private - View Profile | | Biogen Idec Inc. | BIIB | 46.92 | -1.12% | 13.57B | 15.70 | | Genzyme Corp. | GENZ | 51.07 | -0.87% | 13.55B | 29.12 | | Merck Serono S.A. | Private - View Profile | | Chiron Corporation | Private - View Profile | | Gilead Sciences Inc. | GILD | 46.56 | -0.89% | 41.90B | 18.00 | | MedImmune, Inc. | Private - View Profile | | Life Technologies Corporation | LIFE | 49.95 | -1.85% | 8.91B | 1019.39 | | Teva Pharmaceutical Industries Limited | TEVA | 52.88 | -0.53% | 46.59B | 48.38 |
|
| GENERIC DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Sandoz International GmbH | Private - View Profile | | Watson Pharmaceuticals Inc. | WPI | 36.96 | -2.25% | 3.92B | 19.05 | | Barr Pharmaceuticals, Inc. | Private - View Profile | | King Pharmaceuticals Inc. | KG | 11.95 | -1.08% | 2.97B | N/A | | Ranbaxy Laboratories Limited | Private - View Profile | | Mylan, Inc. | MYL | 18.01 | -1.53% | 5.50B | 110.49 | | Pfizer Inc. | PFE | 18.25 | -1.83% | 147.27B | 15.16 | | Johnson & Johnson | JNJ | 62.89 | -0.65% | 173.52B | 13.73 | | GlaxoSmithKline plc | GSK | 42.26 | -1.45% | 107.13B | 13.21 | | Sanofi-Aventis | SNY | 38.43 | -2.61% | 100.35B | N/A |
|
| DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Novartis AG | NVS | 55.38 | -0.84% | 125.78B | 16.58 | | RHHBY.PK | 41.46 | -1.96% | N/A | N/A | | AstraZeneca plc | AZN | 45.29 | -2.35% | 65.67B | 9.09 | | Abbott Laboratories | ABT | 54.08 | -0.61% | 83.65B | 14.65 | | Bristol-Myers Squibb Co. | BMY | 25.38 | -1.05% | 50.28B | 13.13 |
|
| NEWS ON DIRECT COMPETITORS | |
|
|
|